FEM1B: A Drug Target / Disease Biomarker (G10116)
FEM1B: A Drug Target / Disease Biomarker
FEM1B, also known as ZK-PAC-1, is a protein that is expressed in the endoplasmic reticulum (ER) and is involved in the regulation of cell growth, differentiation, and survival. It has been shown to play a role in a variety of diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. As a result, FEM1B has potential as a drug target or biomarker.
One of the main functions of FEM1B is to regulate the levels of intracellular calcium (Ca2+) in cells. Ca2+ is a critical signaling molecule that plays a role in many cellular processes, including muscle contractions, nerve function, and cell signaling. However, high levels of Ca2+ can also contribute to the development of certain diseases, such as cancer and neurodegenerative disorders.
FEM1B has been shown to play a role in the regulation of Ca2+ levels in various cell types. For example, studies have shown that FEM1B levels are elevated in cancer cells compared to normal cells, and that inhibiting FEM1B activity can lead to the regression of cancer tumors. Additionally, FEM1B has been shown to play a role in the regulation of neural stem cell (NSC) differentiation and survival. High levels of FEM1B have been shown to contribute to the decreased survival of NSC, while inhibiting FEM1B activity has been shown to increase the survival of NSC.
FEM1B has also been shown to play a role in the regulation of cellular signaling pathways that are involved in many diseases, including cancer, neurodegenerative disorders, and autoimmune disorders. For example, studies have shown that FEM1B is involved in the regulation of the TGF-β pathway, which is involved in the development and maintenance of tissues and organs. Additionally, FEM1B has been shown to play a role in the regulation of the NF-kappa-B pathway, which is involved in inflammation and cellular signaling.
FEM1B has also been shown to be involved in the regulation of the cytoskeleton, which is the structure that gives cells shape and stability. Studies have shown that FEM1B is involved in the regulation of microtubule dynamics and stability, which are important for cell division and growth.
In conclusion, FEM1B is a protein that is involved in the regulation of many cellular processes that are important for the development and maintenance of health. As a result, FEM1B has potential as a drug target or biomarker for a variety of diseases. Further research is needed to fully understand the role of FEM1B in these diseases and to develop effective treatments.
Protein Name: Fem-1 Homolog B
Functions: Substrate-recognition component of a Cul2-RING (CRL2) E3 ubiquitin-protein ligase complex of the DesCEND (destruction via C-end degrons) pathway, which recognizes a C-degron located at the extreme C terminus of target proteins, leading to their ubiquitination and degradation (PubMed:29779948, PubMed:33398170, PubMed:33398168). The C-degron recognized by the DesCEND pathway is usually a motif of less than ten residues and can be present in full-length proteins, truncated proteins or proteolytically cleaved forms (PubMed:29779948, PubMed:33398170, PubMed:33398168). The CRL2(FEM1B) complex specifically recognizes proteins ending with -Gly-Leu-Asp-Arg, such as CDK5R1, leading to their ubiquitination and degradation (PubMed:33398170, PubMed:33398168). Also acts as a regulator of the reductive stress response by mediating ubiquitination of reduced FNIP1: in response to reductive stress, the CRL2(FEM1B) complex specifically recognizes a conserved Cys degron in FNIP1 when this degron is reduced, leading to FNIP1 degradation and subsequent activation of mitochondria to recalibrate reactive oxygen species (ROS) (By similarity). Promotes ubiquitination of GLI1, suppressing GLI1 transcriptional activator activity (PubMed:24076122). Promotes ubiquitination and degradation of ANKRD37 (By similarity). Promotes ubiquitination and degradation of SLBP (PubMed:28118078). Involved in apoptosis by acting as a death receptor-associated protein that mediates apoptosis (PubMed:10542291). Also involved in glucose homeostasis in pancreatic islet (By similarity). May also act as an adapter/mediator in replication stress-induced signaling that leads to the activation of CHEK1 (PubMed:19330022)
The "FEM1B Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about FEM1B comprehensively, including but not limited to:
• general information;
• protein structure and compound binding;
• protein biological mechanisms;
• its importance;
• the target screening and validation;
• expression level;
• disease relevance;
• drug resistance;
• related combination drugs;
• pharmacochemistry experiments;
• related patent analysis;
• advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai
More Common Targets
FEM1C | FEN1 | FENDRR | FER | FER1L4 | FER1L5 | FER1L6 | FER1L6-AS1 | FER1L6-AS2 | FERD3L | FERMT1 | FERMT2 | FERMT3 | Ferritin | FES | Fetal Hemoglobin (HbF) | FETUB | FEV | FEZ1 | FEZ2 | FEZF1 | FEZF1-AS1 | FEZF2 | FFAR1 | FFAR2 | FFAR3 | FFAR4 | FGA | FGB | FGD1 | FGD2 | FGD3 | FGD4 | FGD5 | FGD5-AS1 | FGD5P1 | FGD6 | FGF1 | FGF10 | FGF10-AS1 | FGF11 | FGF12 | FGF12-AS2 | FGF13 | FGF13-AS1 | FGF14 | FGF14-AS1 | FGF14-AS2 | FGF14-IT1 | FGF16 | FGF17 | FGF18 | FGF19 | FGF2 | FGF20 | FGF21 | FGF22 | FGF23 | FGF3 | FGF4 | FGF5 | FGF6 | FGF7 | FGF7P3 | FGF7P5 | FGF7P6 | FGF8 | FGF9 | FGFBP1 | FGFBP2 | FGFBP3 | FGFR1 | FGFR1OP2 | FGFR2 | FGFR3 | FGFR3P1 | FGFR4 | FGFRL1 | FGG | FGGY | FGL1 | FGL2 | FGR | FH | FHAD1 | FHDC1 | FHF Complex | FHIP1A | FHIP1B | FHIP2A | FHIP2B | FHIT | FHL1 | FHL2 | FHL3 | FHL5 | FHOD1 | FHOD3 | FIBCD1 | FIBIN
